Journal of Clinical Oncology, Vol 15, 2589-2595, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy

S Leyvraz, V Spataro, J Bauer, S Pampallona, R Salmon, T Dorval, R Meuli, M Gillet, F Lejeune and L Zografos
Centre Pluridisciplinaire d'Oncologie and Department of Ophthalmology, University Hospital, Lausanne, Switzerland. serge.leyvraz@chuv.hospvd.ch

PURPOSE: Ocular melanoma is characterized by a high rate of liver metastases and is associated with a median survival time less than 5 months. There is no standard treatment available. Treatment strategies have, without success, relied on the experience with metastatic cutaneous melanoma. The only effective treatment is chemoembolization using cisplatin and polyvinyl sponge, which has never become accepted on a large scale. The objective of the study was to establish prospectively the efficacy and toxicity of hepatic intraarterial fotemustine, a third-generation nitrosourea, in patients with liver metastases from ocular melanoma. PATIENTS AND METHODS: Thirty-one patients were subjected to laparotomy to place a totally implantable catheter into the hepatic artery and received fotemustine 100 mg/m2 as a 4-hour infusion, first once a week for four times and then, after a 5- week rest period, every 3 weeks until progression or toxicity. Cox regression models were used to assess the prognostic role of patient survival characteristics. RESULTS: Objective responses were observed in 12 of 30 assessable patients (40%; 95% confidence interval, 22% to 59%). The median duration of response was 11 months and the median overall survival time, 14 months. Lactate dehydrogenase (LDH) appeared to be the strongest prognostic factor for survival. Toxicity was minimal and treatment could be administered on an outpatient basis. CONCLUSION: The results of hepatic arterial chemotherapy with fotemustine produced a high response rate and survival similar to chemoembolization therapy. It involves no major toxicity and preserves the quality of life. To assess further its effectiveness, a randomized study to compare hepatic intraarterial versus intravenous chemotherapy is being planned.

This article has been cited by other articles:

				T. Sato, D. J. Eschelman, C. F. Gonsalves, M. Terai, I. Chervoneva, P. A. McCue, J. A. Shields, C. L. Shields, A. Yamamoto, D. Berd, et al. Immunoembolization of Malignant Liver Tumors, Including Uveal Melanoma, Using Granulocyte-Macrophage Colony-Stimulating Factor J. Clin. Oncol., November 20, 2008; 26(33): 5436 - 5442. [Abstract] [Full Text] [PDF]

				M. Buijs, J. A. Vossen, K. Hong, C. S. Georgiades, J.-F. H. Geschwind, and I. R. Kamel Chemoembolization of Hepatic Metastases from Ocular Melanoma: Assessment of Response with Contrast-Enhanced and Diffusion-Weighted MRI Am. J. Roentgenol., July 1, 2008; 191(1): 285 - 289. [Abstract] [Full Text] [PDF]

				K. V. Sharma, J. E. Gould, J. W. Harbour, G. P. Linette, T. K. Pilgram, P. N. Dayani, and D. B. Brown Hepatic Arterial Chemoembolization for Management of Metastatic Melanoma Am. J. Roentgenol., January 1, 2008; 190(1): 99 - 104. [Abstract] [Full Text] [PDF]

				S. Peters, V. Voelter, L. Zografos, S. Pampallona, R. Popescu, M. Gillet, W. Bosshard, G. Fiorentini, M. Lotem, R. Weitzen, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients Ann. Onc., April 1, 2006; 17(4): 578 - 583. [Abstract] [Full Text] [PDF]

				P T Finger, M Kurli, S Reddy, L B Tena, and A C Pavlick Whole body PET/CT for initial staging of choroidal melanoma Br. J. Ophthalmol., October 1, 2005; 89(10): 1270 - 1274. [Abstract] [Full Text] [PDF]

				H. R. Alexander Jr. A Motion for Cautious Optimism in the Treatment of Patients With Ocular Melanoma: The Ayes Have It Ann. Surg. Oncol., June 1, 2005; 12(6): 417 - 419. [Full Text] [PDF]

				M. Rivoire, L. Kodjikian, S. Baldo, P. Kaemmerlen, S. Negrier, and J.-D. Grange Treatment of Liver Metastases From Uveal Melanoma Ann. Surg. Oncol., June 1, 2005; 12(6): 422 - 428. [Abstract] [Full Text] [PDF]

				A. Grover and H. R. Alexander Jr. The Past Decade of Experience With Isolated Hepatic Perfusion Oncologist, November 1, 2004; 9(6): 653 - 664. [Abstract] [Full Text] [PDF]

				M. Diener-West, S. M. Reynolds, D. J. Agugliaro, R. Caldwell, K. Cumming, J. D. Earle, D. L. Green, B. S. Hawkins, J. Hayman, I. Jaiyesimi, et al. Screening for Metastasis From Choroidal Melanoma: The Collaborative Ocular Melanoma Study Group Report 23 J. Clin. Oncol., June 15, 2004; 22(12): 2438 - 2444. [Abstract] [Full Text] [PDF]

				E. D. Feldman, J. F. Pingpank, and H. R. Alexander Jr. Regional Treatment Options for Patients With Ocular Melanoma Metastatic to the Liver Ann. Surg. Oncol., March 1, 2004; 11(3): 290 - 297. [Abstract] [Full Text] [PDF]

				H. R. Alexander Jr., S. K. Libutti, J. F. Pingpank, S. M. Steinberg, D. L. Bartlett, C. Helsabeck, and T. Beresneva Hyperthermic Isolated Hepatic Perfusion Using Melphalan for Patients with Ocular Melanoma Metastatic to Liver Clin. Cancer Res., December 15, 2003; 9(17): 6343 - 6349. [Abstract] [Full Text] [PDF]

				S Eskelin and T Kivela Mode of presentation and time to treatment of uveal melanoma in Finland Br. J. Ophthalmol., March 1, 2002; 86(3): 333 - 338. [Abstract] [Full Text] [PDF]

				The Collaborative Ocular Melanoma Study Group The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, III: Initial Mortality Findings: COMS Report No. 18 Arch Ophthalmol, July 1, 2001; 119(7): 969 - 982. [Abstract] [Full Text] [PDF]

				H. R. Alexander Jr., D. L. Bartlett, and S. K. Libutti Current Status of Isolated Hepatic Perfusion With or Without Tumor Necrosis Factor for the Treatment of Unresectable Cancers Confined to Liver Oncologist, October 1, 2000; 5(5): 416 - 424. [Abstract] [Full Text]

				H. R. Alexander, S. K. Libutti, D. L. Bartlett, M. Puhlmann, D. L. Fraker, and L. C. Bachenheimer A Phase I-II Study of Isolated Hepatic Perfusion Using Melphalan with or without Tumor Necrosis Factor for Patients with Ocular Melanoma Metastatic to Liver Clin. Cancer Res., August 1, 2000; 6(8): 3062 - 3070. [Abstract] [Full Text]

				J-M LUTZ, I A CREE, and A J FOSS Risk factors for intraocular melanoma and occupational exposure Br. J. Ophthalmol., October 1, 1999; 83(10): 1190 - 1193. [Full Text]